n,n-dimethylarginine has been researched along with dapagliflozin in 1 studies
| Studies (n,n-dimethylarginine) | Trials (n,n-dimethylarginine) | Recent Studies (post-2010) (n,n-dimethylarginine) | Studies (dapagliflozin) | Trials (dapagliflozin) | Recent Studies (post-2010) (dapagliflozin) |
|---|---|---|---|---|---|
| 2,216 | 228 | 1,221 | 1,478 | 368 | 1,407 |
| Protein | Taxonomy | n,n-dimethylarginine (IC50) | dapagliflozin (IC50) |
|---|---|---|---|
| Sodium/glucose cotransporter 1 | Homo sapiens (human) | 1.1661 | |
| Sodium/glucose cotransporter 2 | Homo sapiens (human) | 0.0022 | |
| Sodium/myo-inositol cotransporter 2 | Homo sapiens (human) | 0.38 | |
| Solute carrier family 5 member 4 | Homo sapiens (human) | 0.0014 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bosch, A; Fromm, MF; Gemeinhardt, A; Gessner, A; Kannenkeril, D; Maas, R; Mayr, A; Schmieder, RE; Staerk, C | 1 |
1 trial(s) available for n,n-dimethylarginine and dapagliflozin
| Article | Year |
|---|---|
Effects of treatment with SGLT-2 inhibitors on arginine-related cardiovascular and renal biomarkers.
Topics: Arginine; Benzhydryl Compounds; Biomarkers; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Male; Middle Aged; Predictive Value of Tests; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome | 2022 |